Reddit Posts
Mentions
Before I come off as extremely rude, I did read this and believe you’re in fact a young kid interested in finance and should continue to pursue this interest because it’s a great start. As per your post, you mention a lot of things that are technically correct, but result in an over-engineered, fundamentally disjointed strategy that conflates a lot of options jargon that is irrelevant or impractical for profitability, like over-emphasizing a Greek profile that is doesn’t make sense from a risk standpoint. High level first. LEAPS only describe the length of time til exp. And can be used in a number of profitable ways. Your strategy, being a mean reversion, fundamental value-based “transaction” as you so gracefully call it, play doesn’t fit your Greek criteria. KROS, any biotech stock or any mean reversion play could never meet these because IV and Vega spike. This is the event-based action being priced in. Key concept: everything is priced in. So you end up screening out the very opportunities you’re targeting, or forcing yourself into deep ITM contracts that dilute convexity and capital efficiency, turning the whole thing into synthetic stock with extra friction. I get what you mean by wanting these to be low because you want to pay as little as possible but it becomes a simple directional bet with the added drag of theta. The set up makes sense (in theory) but controlling sensitivity it doesn’t change the economics behind the risk the option’s intrinsic value has reached a predefined threshold (say, 80-120% Also intrinsic value cannot be over 100%
Before I come off as extremely rude, I did read this and believe you’re in fact a young kid interested in finance and should continue to pursue this interest because it’s a great start. As per your post, you mention a lot of things that are technically correct, but result in an over-engineered, fundamentally disjointed strategy that conflates a lot of options jargon that is irrelevant or impractical for profitability, like over-emphasizing a Greek profile that is doesn’t make sense from a risk standpoint. High level first. LEAPS only describe the length of time til exp. And can be used in a number of profitable ways. Your strategy, being a mean reversion, fundamental value-based “transaction” as you so gracefully call it, play doesn’t fit your Greek criteria. KROS, any biotech stock or any mean reversion play could never meet these because IV and Vega spike. This is the event-based action being priced in. Key concept: everything is priced in. So you end up screening out the very opportunities you’re targeting, or forcing yourself into deep ITM contracts that dilute convexity and capital efficiency, turning the whole thing into synthetic stock with extra friction. I get what you mean by wanting these to be low because you want to pay as little as possible but it becomes a simple directional bet with the added drag of theta. The set up makes sense (in theory) but controlling sensitivity it doesn’t change the economics behind the risk > the option’s intrinsic value has reached a predefined threshold (say, 80-120% Also intrinsic value cannot be over 100%
VIR MYNZ KROS Biotechs on FIRE today
Damn KROS dropped 2%. I doubted. Now it’s green I didn't buy the dip
Any visibility of what is on for NMRA and KROS? Been in those stocks for sometime now, buying at all the dips but waiting for a trigger.
My understanding is that KROS is not developing AAV based therapies so it is not at at all similar to TNYA
KROS is down about 80% and likely will recover soon
I gamble a lot, yeah. Mostly biotech and trends. I wouldn't say I'm smart, but the plays I win on outweigh my losses. If you aren't cringe in chat, you can come over to Godel Terminal. Reddit is full of regards, but godel is Martin Shkreli's self funded Bloomberg terminal type trading platform. All financial you want, all news, and there's a free trial to see the chat. Full of people calling great plays. Martin will even evaluate a company you request on livestream with everyone. I've made *real* money since joining them vs hanging out in wsb. Like .01 to 33.51 shorts on KROS last week for a drug fail. The people in there actually know business, tech, and bio instead of 15year olds doing DD for robinhood plays.
I think $KROS is a good long. They’re not dead- this is a temporary setback given previous good results at lower doses. But why the hell are these option premiums so high! $2.65 for Jan 17- $20 for something that just plummeted 70%
KROS stopped the trial because of adverse reactions. Fluid was building up around the hearts of trial patients. TNYA hasn’t had anything like this happen. They would have already pulled the plug if anything had happened to trial patients.
That sort of makes sense but sort of doesn’t. KROS stopped the trial because of adverse reactions. Fluid was building up around the hearts of trial patients. TNYA hasn’t had anything like this happen. They would have already pulled the plug if anything had happened to trial patients.
Some have been speculating that it could be from the news $KROS dropped this morning and could have spooked an institution that is holding $TNYA, but just something to make notice of. I’m still zen, just waiting on news
Could be from the news coming from $KROS, where they had to halt their dosing in their trial which is somewhat similar to what $TNYA is developing. I don’t know if that was it but could have spooked an institution that was holding it but I’m not too worried, all depends on their news release
What is happening with KROS? Losing 75% today
KROS must have had some good news
I’ve been watching $SKYE and a few other small and mid cap obesity drug stocks. But I want to find a company whos stock hasn’t had a huge run up yet. Anyone watching anything interesting ? There’s lots of problems with GLP-1 technology and a small guy will do it. $BHVN $SRRK $KROS
The small cap obesity stocks are insane like $SAVA $SRRK $BHVN $KROS
been watching KROS went from 35 to 44 today and i can't even find one person talking about it
Looking at KROS performance maybe Spruce isn't meeting profit targets and hence this ABML hit piece.